BRAF and PRKACA

Data Source:
HPRD (in vivo, in vitro)

		BRAF	PRKACA
Description		B-Raf proto-oncogene, serine/threonine kinase	protein kinase cAMP-activated catalytic subunit alpha
Image
GO Annotations	Cellular Component	Nucleus Cytosol Plasma Membrane Intracellular Membrane-bounded Organelle	Acrosomal Vesicle Nucleus Nucleoplasm Cytoplasm Mitochondrion Centrosome Cytosol Axoneme CAMP-dependent Protein Kinase Complex Membrane Nuclear Speck Neuromuscular Junction Calcium Channel Complex Sperm Flagellum Dendritic Spine Plasma Membrane Raft Perinuclear Region Of Cytoplasm Extracellular Exosome Ciliary Base
	Molecular Function	Protein Kinase Activity Protein Serine/threonine Kinase Activity Calcium Ion Binding Protein Binding ATP Binding Small GTPase Binding Identical Protein Binding Scaffold Protein Binding Protein Serine Kinase Activity Protein Threonine Kinase Activity	Magnesium Ion Binding Protein Kinase Activity Protein Serine/threonine Kinase Activity AMP-activated Protein Kinase Activity CAMP-dependent Protein Kinase Activity Protein Serine/threonine/tyrosine Kinase Activity Protein Binding ATP Binding Protein Kinase Binding Protein Domain Specific Binding Manganese Ion Binding Ubiquitin Protein Ligase Binding Protein Kinase A Regulatory Subunit Binding
	Biological Process	MAPK Cascade Activation Of MAPKK Activity Protein Phosphorylation Epidermal Growth Factor Receptor Signaling Pathway Animal Organ Morphogenesis Positive Regulation Of Gene Expression Positive Regulation Of Glucose Transmembrane Transport Positive Regulation Of Peptidyl-serine Phosphorylation Negative Regulation Of Apoptotic Process Positive Regulation Of ERK1 And ERK2 Cascade Trehalose Metabolism In Response To Stress Cellular Response To Calcium Ion Establishment Of Protein Localization To Membrane	G2/M Transition Of Mitotic Cell Cycle Mesoderm Formation Neural Tube Closure Regulation Of Heart Rate Stimulatory C-type Lectin Receptor Signaling Pathway Renal Water Homeostasis MRNA Processing Protein Phosphorylation Blood Coagulation Regulation Of G2/M Transition Of Mitotic Cell Cycle Protein Kinase A Signaling Regulation Of Cardiac Muscle Contraction By Regulation Of The Release Of Sequestered Calcium Ion Regulation Of Macroautophagy Peptidyl-serine Phosphorylation Peptidyl-threonine Phosphorylation Cytokine-mediated Signaling Pathway Activation Of Protein Kinase A Activity High-density Lipoprotein Particle Assembly Cellular Response To Heat Calcium-mediated Signaling Using Intracellular Calcium Source Regulation Of Protein Binding Regulation Of Osteoblast Differentiation Protein Autophosphorylation Positive Regulation Of Protein Export From Nucleus Sperm Capacitation Modulation Of Chemical Synaptic Transmission Regulation Of Cytosolic Calcium Ion Concentration Regulation Of Cardiac Muscle Contraction Regulation Of Ryanodine-sensitive Calcium-release Channel Activity Regulation Of Proteasomal Protein Catabolic Process Regulation Of Protein Processing Positive Regulation Of Cell Cycle Arrest Cellular Response To Glucose Stimulus Cellular Response To Parathyroid Hormone Stimulus Cellular Response To Glucagon Stimulus Cellular Response To Epinephrine Stimulus Cell Communication By Electrical Coupling Involved In Cardiac Conduction Ciliary Basal Body-plasma Membrane Docking Negative Regulation Of Smoothened Signaling Pathway Involved In Dorsal/ventral Neural Tube Patterning Regulation Of Cardiac Conduction Regulation Of Bicellular Tight Junction Assembly
Pathways		Spry regulation of FGF signaling Frs2-mediated activation Frs2-mediated activation ARMS-mediated activation Signalling to p38 via RIT and RIN RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants Signaling by MRAS-complex mutants	PKA-mediated phosphorylation of CREB PKA-mediated phosphorylation of key metabolic factors Triglyceride catabolism PKA activation PKA activation in glucagon signalling DARPP-32 events Regulation of PLK1 Activity at G2/M Transition Loss of Nlp from mitotic centrosomes Recruitment of mitotic centrosome proteins and complexes Loss of proteins required for interphase microtubule organization from the centrosome Recruitment of NuMA to mitotic centrosomes Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Glucagon-like Peptide-1 (GLP1) regulates insulin secretion Rap1 signalling Regulation of insulin secretion Vasopressin regulates renal water homeostasis via Aquaporins VEGFA-VEGFR2 Pathway CREB1 phosphorylation through the activation of Adenylate Cyclase CREB1 phosphorylation through the activation of Adenylate Cyclase Interleukin-3, Interleukin-5 and GM-CSF signaling Ion homeostasis Degradation of GLI1 by the proteasome Degradation of GLI2 by the proteasome GLI3 is processed to GLI3R by the proteasome Hedgehog 'off' state Anchoring of the basal body to the plasma membrane CD209 (DC-SIGN) signaling MAPK6/MAPK4 signaling RET signaling AURKA Activation by TPX2 HDL assembly ROBO receptors bind AKAP5 Loss of phosphorylation of MECP2 at T308 Regulation of MECP2 expression and activity Regulation of glycolysis by fructose 2,6-bisphosphate metabolism ADORA2B mediated anti-inflammatory cytokines production ADORA2B mediated anti-inflammatory cytokines production FCGR3A-mediated IL10 synthesis FCGR3A-mediated IL10 synthesis Factors involved in megakaryocyte development and platelet production
Drugs		Sorafenib XL281 RAF-265 PLX-4720 N-{2,4-difluoro-3-[(5-pyridin-3-yl-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]phenyl}ethanesulfonamide (1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime Vemurafenib Regorafenib Dabrafenib Encorafenib Fostamatinib Ripretinib	Pentanal Balanol Analog 2 3-[(3-sec-butyl-4-hydroxybenzoyl)amino]azepan-4-yl 4-(2-hydroxy-5-methoxybenzoyl)benzoate Phosphonothreonine Balanol Analog 1 3,5-Diiodotyrosine Balanol Dexfosfoserine S,S-(2-Hydroxyethyl)Thiocysteine Hydroxyfasudil (2S)-1-(3H-Indol-3-yl)-3-{[5-(6-isoquinolinyl)-3-pyridinyl]oxy}-2-propanamine (2S)-1-{[5-(1H-Indazol-5-yl)-3-pyridinyl]oxy}-3-(7aH-indol-3-yl)-2-propanamine (1S)-2-(1H-INDOL-3-YL)-1-[({5-[(E)-2-PYRIDIN-4-YLVINYL]PYRIDIN-3-YL}OXY)METHYL]ETHYLAMINE (2S)-1-(6H-INDOL-3-YL)-3-{[5-(7H-PYRAZOLO[3,4-C]PYRIDIN-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE (1S)-1-(1H-INDOL-3-YLMETHYL)-2-(2-PYRIDIN-4-YL-[1,7]NAPHTYRIDIN-5-YLOXY)-EHYLAMINE N-[(1S)-2-AMINO-1-(2,4-DICHLOROBENZYL)ETHYL]-5-[2-(METHYLAMINO)PYRIMIDIN-4-YL]THIOPHENE-2-CARBOXAMIDE 3-(1H-indol-3-yl)-4-{1-[2-(1-methylpyrrolidin-2-yl)ethyl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione (4R,2S)-5'-(4-(4-CHLOROBENZYLOXY)PYRROLIDIN-2-YLMETHANESULFONYL)ISOQUINOLINE N-METHYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE (S)-1-PHENYL-1-[4-(9H-PURIN-6-YL)PHENYL]METHANAMINE 6-{4-[4-(4-CHLOROPHENYL)PIPERIDIN-4-YL]PHENYL}-9H-PURINE (2R)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine (2S)-2-(4-chlorophenyl)-2-[4-(1H-pyrazol-4-yl)phenyl]ethanamine 4-(4-CHLOROPHENYL)-4-[4-(1H-PYRAZOL-4-YL)PHENYL]PIPERIDINE (2R)-2-(4-CHLOROPHENYL)-2-PHENYLETHANAMINE (S)-2-METHYL-1-[(4-METHYL-5-ISOQUINOLINE)SULFONYL]-HOMOPIPERAZINE ISOQUINOLINE-5-SULFONIC ACID (2-(2-(4-CHLOROBENZYLOXY)ETHYLAMINO)ETHYL)AMIDE H-89 5-(2-methylpiperazine-1-sulfonyl)isoquinoline N-[2-(METHYLAMINO)ETHYL]-5-ISOQUINOLINESULFONAMIDE 2-[4-(3-METHYL-1H-PYRAZOL-4-YL)PHENYL]ETHANAMINE (2S)-1-(1H-INDOL-3-YL)-3-{[5-(3-METHYL-1H-INDAZOL-5-YL)PYRIDIN-3-YL]OXY}PROPAN-2-AMINE 3-pyridin-4-yl-1H-indazole 5-benzyl-1,3-thiazol-2-amine 1-[4-(4-chlorophenyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine 1-[4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-yl]methanamine 4-(4-chlorobenzyl)-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidin-4-aminium Fasudil Myristic acid A-674563 3-PYRIDIN-4-YL-2,4-DIHYDRO-INDENO[1,2-.C.] PYRAZOLE Y-27632 Ellagic acid Fostamatinib
Diseases		Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS) Thyroid cancer Malignant melanoma
GWAS		anorexia nervosa, attention-deficit/hyperactivity disorder, autism spectrum disorder, bipolar disorder, major depression, obsessive-compulsive disorder, schizophrenia, or Tourette syndrome (pleiotropy) ( 31835028) Bipolar disorder ( 31043756) Cerebrospinal fluid t-tau:AB1-42 ratio ( 26252872) Cerebrospinal T-tau levels ( 26252872) Mild influenza (H1N1) infection ( 26379185) Response to Vitamin E supplementation ( 22437554) Type 2 diabetes ( 32499647 28869590)
Interacting Genes		46 interacting genes: AKT1 ARAF AURKA BAD CCDC88A CTSV FBP1 HRAS HSD17B3 ITCH KRAS LATS2 MAP2K1 MAP2K2 MAP2K3 MAP2K6 MAPK1 MAPK3 MRAS NANOG OIP5 PAK2 PEBP1 PPP2CA PPP2R2A PRKACA PRKCE RAF1 RAP1A RAP1GAP RASSF1 RHEB SFN SGK1 SPRY2 STK11 TERF1 TERT UBE2L3 YWHAB YWHAG YWHAH YWHAQ YWHAZ ZNF189 ZNF510	205 interacting genes: AANAT ABCA1 ACLY ADCY5 ADD1 ADD2 AKAP14 AKAP8L AKIP1 ANXA7 APC APOBEC3G ARFGEF3 ASIC1 ASIC3 ATF1 ATP2B1 AURKA AVPI1 BAD BCL2 BRAF CACNA1C CACNB2 CACNG2 CAD CALD1 CAMKK2 CCDC88A CCND1 CDK16 CDKN1A CETN1 CFTR CIITA CLDN3 CLTC CREB1 CREM CRK CSK CUL5 CYP3A4 DMTN DNAJC5 DOCK1 DRD1 DSP EEF2K EGFR ERBB3 ESR1 ETV1 FBXW11 FOS FXYD1 GABRB3 GABRR1 GAD1 GAD2 GFAP GJA5 GJB1 GLI1 GMFB GNA13 GNMT GP1BB GRIA1 GRIA4 GRK2 GSK3A GSK3B GUSB GYS1 HAND1 HAND2 HDAC1 HDAC8 HIF1A HMGCR HMGN1 HMGN2 HNF4A HNRNPD HSP90AA1 HSPA4 HSPD1 IFNAR1 IQGAP1 IRF2 ITCH ITGA2B ITGA4 ITPKA ITPKB ITPR1 ITPR2 KCNH2 KCNJ12 KCNQ1 KDELR1 KLF1 KLHL3 LCK LCP1 LIPE LRP1 MAP2 MAP3K3 MAPT MBP MC4R MEF2D MEP1B MGMT MIP NDRG1 NFKB1 NIN NOLC1 NOS1 NOXA1 NR3C1 NSFL1C NUP85 PDC PDE3A PDE3B PDE4B PDE4D PDPK1 PFKFB1 PFKFB2 PHKA1 PHOX2A PKIA PKIB PLIN1 PLN POU2F1 PPP1R10 PPP1R17 PPP1R1B PPP1R8 PPP1R9B PRKAR1A PRKAR1B PRKAR2B PSEN1 PSMD11 PTBP1 PTPN12 PTPN13 PTPN7 PTPRR RAF1 RANBP9 RAP1A RAP1B RAP1GAP RASGRF1 RASGRP3 RELA RGS10 RGS13 RGS14 RHOA RRAD RSBN1 RYR1 RYR2 SI SIK1 SIK3 SLC2A2 SLC4A4 SLC9A3R2 SNAP25 SNAPIN SNPH SPTBN1 SRC STK11 STMN1 STMN2 STUB1 SYN1 SYN2 TH THOP1 TNP1 TNP2 TPH1 TRIM55 TRIM63 TRIP10 UBE3A UHRF1 USP20 VASP VIM VTN WT1 YWHAZ
Entrez ID		673	5566
HPRD ID		01264	03382
Ensembl ID		ENSG00000157764	ENSG00000072062
Uniprot IDs		P15056	A0A024R7J0 A8K8B9 P17612
PDB IDs		1UWH 1UWJ 2FB8 2L05 3C4C 3D4Q 3IDP 3II5 3NY5 3OG7 3PPJ 3PPK 3PRF 3PRI 3PSB 3PSD 3Q4C 3Q96 3SKC 3TV4 3TV6 4CQE 4DBN 4E26 4E4X 4EHE 4EHG 4FC0 4FK3 4G9C 4G9R 4H58 4JVG 4KSP 4KSQ 4MBJ 4MNE 4MNF 4PP7 4R5Y 4RZV 4RZW 4WO5 4XV1 4XV2 4XV3 4XV9 4YHT 5C9C 5CSW 5CSX 5CT7 5FD2 5HI2 5HID 5HIE 5ITA 5J17 5J18 5J2R 5JRQ 5JSM 5JT2 5VAL 5VAM 5VR3 5VYK 6B8U 6CAD 6N0P 6N0Q 6NSQ 6NYB 6P3D 6P7G 6PP9 6Q0J 6Q0K 6Q0T 6U2G 6U2H 6UAN 6UUO 6XAG	2GU8 3AGL 3AGM 3AMA 3AMB 3L9L 3L9M 3L9N 3MVJ 3NX8 3OOG 3OVV 3OWP 3OXT 3P0M 3POO 3VQH 4AE6 4AE9 4UJ1 4UJ2 4UJ9 4UJA 4UJB 4WB5 4WB6 4WB7 4WB8 5BX6 5BX7 5IZF 5IZJ 5J5X 5N23 5UZK 6BYR 6BYS 6C0U 6FRX 6NO7 6QJ7
Enriched GO Terms of Interacting Partners?
Tagcloud ?
Tagcloud (Difference) ?
Tagcloud (Intersection) ?